---
figid: PMC7388413__OR-44-03-0863-g00
figtitle: The PI3K pathway in cancer cells
organisms:
- Homo sapiens
- Mus musculus
- unidentified
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC7388413
filename: OR-44-03-0863-g00.jpg
figlink: pmc/articles/PMC7388413/figure/f1-or-44-03-0863/
number: F1
caption: Mechanisms of the PI3K pathway in cancer cells. Cetuximab is a molecular
  targeted agent against epidermal growth factor receptor, while alpelisib is a selective
  PI3Kα inhibitor.
papertitle: Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab-resistant
  oral squamous cell carcinoma.
reftext: Hiroki Tsuchihashi, et al. Oncol Rep. 2020 Sep;44(3):863-872.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9693755
figid_alias: PMC7388413__F1
figtype: Figure
redirect_from: /figures/PMC7388413__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7388413__OR-44-03-0863-g00.html
  '@type': Dataset
  description: Mechanisms of the PI3K pathway in cancer cells. Cetuximab is a molecular
    targeted agent against epidermal growth factor receptor, while alpelisib is a
    selective PI3Kα inhibitor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - EGFR
  - PI3
  - RICTOR
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - Egfr
  - Serpina1c
  - Pik3r1
  - Pik3ca
  - Akt1
  - Mtor
  - Rps6kb1
  - Eif4ebp1
  - pi
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - S6k
  - Thor
---
